Core Insights - Fennec Pharmaceuticals announced the grant of incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan, totaling 377,500 shares [1][2] Group 1: Stock Options and Inducement Plan - The incentive stock options (ISOs) have an exercise price of $5.77 per share, equal to the closing price on March 30, 2026, and a term of ten years from the grant date [3] - One-third of the shares underlying each ISO will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following 24 months, contingent on continued employment [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its primary product being PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity [4] - PEDMARK received FDA approval in September 2022, followed by European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI [4] - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [5]

Core Insights - Fennec Pharmaceuticals reported record commercial growth for its product PEDMARK, with significant increases in patient support metrics and adoption in both new and existing accounts [7] - The company achieved record net product sales of $44.6 million for 2025, up from $29.6 million in 2024, and fourth-quarter net product sales of $13.8 million, an increase from $7.9 million in the prior-year quarter [6] - Management emphasized the importance of expanding the customer-facing team and improving operational infrastructure to enhance patient conversion rates, which improved from 50% in Q1 to 70% in Q4 [2][4] Marketing and Patient Support - The company is launching initiatives to engage young adult testicular cancer patients, including a partnership for the Indy 500 event and a significant presence at the ASCO meeting [1] - Fennec HEARS, the full-service patient support program, achieved record performance in Q4 with all-time highs in patient enrollments and conversion rates [3] Financial Performance - The fourth quarter marked the fifth consecutive quarter of net product sales growth, attributed to broader account growth and improved conversion and adherence among PEDMARK patients [5] - Selling and marketing expenses rose to $6.1 million in Q4 from $3.9 million a year earlier, while general and administrative expenses increased to $8.9 million from $4.2 million [12][13] - Fennec ended 2025 with $36.8 million in cash and cash equivalents, driven by approximately $42 million in net proceeds from equity offerings [14] Strategic Developments - A settlement of U.S. patent litigation related to PEDMARK was announced, preventing Cipla from entering the market with a generic product until September 1, 2033, which is expected to save the company "multiple millions of dollars" annually [16] - The company is expanding its medical affairs organization and generating new clinical evidence to support PEDMARK's use, with encouraging feedback from clinicians [8][10] Future Outlook - The company anticipates cash operating expenses to rise from approximately $35 million in 2025 to about $50 million in 2026, reflecting investments in commercial and medical functions [18] - Norgine launched PEDMARQSI in the U.K. and Germany in 2025, with plans for 8-10 launches in 2026, expected to contribute to royalty revenues [19] - Ongoing clinical trials in Japan and evaluations at various cancer institutes are expected to enhance the understanding and application of PEDMARK [20][21]

Financial Data and Key Metrics Changes - The company reported record net product sales of $44.6 million for the full year 2025, a 50% increase from $29.6 million in 2024 [5][20] - For Q4 2025, net product sales were $13.8 million, up approximately 75% from $7.9 million in Q4 2024 [19][20] - Selling and marketing expenses for Q4 2025 were $6.1 million, compared to $3.9 million in Q4 2024, reflecting increased payroll and marketing efforts [20][21] - General and administrative expenses for Q4 2025 were $8.9 million, up from $4.2 million in Q4 2024 [21][22] - Cash and cash equivalents stood at $36.8 million as of December 31, 2025, bolstered by $42 million in net proceeds from equity offerings [22][23] Business Line Data and Key Metrics Changes - The Fennec HEARS patient support program achieved record performance in Q4, with significant increases in patient enrollments, prescribed and infused vials, and conversion rates, which rose to 70% in Q4 from 50% in Q1 [8][19] - The company expanded its capabilities to target the adolescent and young adult (AYA) market, enhancing its customer-facing team to increase reach and frequency [6][7] Market Data and Key Metrics Changes - The company is focusing on expanding awareness and use of PEDMARK, particularly among young adult testicular cancer patients, with initiatives planned around events like the Indy 500 and significant presence at the ASCO meeting [9][10] - The company is also advancing its clinical evidence strategy, with ongoing studies in Japan and partnerships with leading academic institutions to generate new clinical data [10][12] Company Strategy and Development Direction - The company aims for global expansion and sustained growth, with a focus on executing its strategic plans and enhancing its operating leverage [11] - The management emphasized a balanced approach to capital allocation, investing in high-impact initiatives while maintaining financial rigor [7][11] - The company is committed to establishing PEDMARK as the standard of care for patients receiving cisplatin, with a focus on expanding clinical evidence and guideline recognition [15][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its plans and achieve long-term value creation, highlighting a strong foundation built in 2025 [11][12] - The management noted that the company anticipates generating positive cash flow in Q1 2026, with early collection of receivables benefiting cash position [23] - The settlement of patent litigation regarding PEDMARK is expected to provide market exclusivity and save on annual G&A expenses, allowing for reinvestment in commercial expansion [23][24] Other Important Information - The company has zero debt outstanding, marking the strongest balance sheet in its history [22][23] - The management is focused on expanding the clinical evidence base for PEDMARK, particularly in the AYA population, and is in ongoing dialogue with regulatory authorities regarding potential label expansions [29][30] Q&A Session Summary Question: What is the biggest challenge or pushback from physicians regarding PEDMARK? - The primary concern has been whether sodium thiosulfate could reduce cisplatin's anti-tumor activity. Long-term follow-up studies have shown no difference in overall survival between the PEDMARK plus cisplatin arm and the cisplatin alone arm, which has helped shift physician confidence [25][26][27] Question: What is Fennec's regulatory strategy for the AYA population? - The company is focused on expanding the clinical evidence base and maintaining dialogue with regulatory authorities regarding potential pathways for label expansion as data matures [29][30] Question: Can you provide an estimate on cash operating expenses for 2026? - Cash operating expenses are anticipated to grow from approximately $35 million in 2025 to about $50 million in 2026, driven by commercial and medical expansions [31][33] Question: Can you provide an update on the Norgine partnership and ex-U.S. progress? - Norgine is planning 8-10 launches in 2026, with initial revenue contributions expected in the second half of 2026 [34][35] Question: When will you provide revenue or EBITDA guidance in 2026? - The company intends to evaluate the potential for issuing revenue and EBITDA guidance as it monitors the impact of growth initiatives throughout the year [36] Question: Can you elaborate on the recent field force expansion? - The expansion is targeted at building territory managers to increase reach and frequency, focusing on high-tier accounts and supporting activation of new centers [37][38] Question: How is the Fennec HEARS program impacting commercial demand? - The program primarily addresses access barriers, ensuring appropriate patients can start and complete therapy, which supports clinical adoption and physician decision-making [39][40]

Financial Data and Key Metrics Changes - The company reported record net product sales of $44.6 million for the full year 2025, a 50% increase from $29.6 million in 2024 [5][20] - For Q4 2025, net product sales were $13.8 million, up approximately 75% from $7.9 million in Q4 2024 [19][20] - Selling and marketing expenses for Q4 2025 were $6.1 million, compared to $3.9 million in Q4 2024, reflecting increased payroll and marketing efforts [20][21] - General and administrative expenses for Q4 2025 were $8.9 million, up from $4.2 million in Q4 2024 [21][22] - Cash and cash equivalents stood at $36.8 million as of December 31, 2025, bolstered by $42 million in net proceeds from equity offerings [22][23] Business Line Data and Key Metrics Changes - The Fennec HEARS patient support program achieved record performance in Q4, with significant increases in patient enrollments, prescribed and infused vials, and conversion rates, which rose to 70% in Q4 from 50% in Q1 [8][19] - The company expanded its capabilities to target the adolescent and young adult (AYA) market, enhancing its customer-facing team to increase reach and frequency [6][7] Market Data and Key Metrics Changes - The company is focusing on expanding awareness and use of PEDMARK, particularly among young adult testicular cancer patients, with initiatives planned around major events like the Indy 500 and the ASCO meeting [9][10] - The company is also making strides in Japan with the STS-J01 clinical trial for PEDMARK, which is crucial for global expansion [10] Company Strategy and Development Direction - The company aims for global expansion and sustained growth, with a focus on execution and enhancing its medical and commercial strategies [11] - The strategic plan includes increasing clinical evidence generation and strengthening relationships with key opinion leaders and academic institutions [12][15] - The company is committed to addressing unmet needs in vulnerable groups, such as AYA and adult patients, through evidence-based initiatives [15][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its plans and achieve long-term value creation, citing a strong balance sheet and disciplined capital allocation [7][22] - The management team highlighted the importance of ongoing engagement with healthcare providers to enhance the adoption of PEDMARK and address concerns regarding its use alongside cisplatin [25][28] Other Important Information - The company announced the settlement of patent litigation regarding PEDMARK, which will provide market exclusivity until September 1, 2033, saving millions in annual G&A expenses [23][24] - The company anticipates generating positive cash flow in Q1 2026, aided by early collection of receivables [23] Q&A Session Summary Question: What is the biggest challenge or pushback from physicians regarding PEDMARK? - The primary concern has been whether sodium thiosulfate interferes with cisplatin's anti-tumor activity. Long-term follow-up data shows no difference in survival outcomes, which has helped shift physician confidence [25][26][27] Question: What is Fennec's regulatory strategy for the AYA population? - The company is focused on expanding clinical evidence and maintaining dialogue with regulatory authorities for potential label expansion as data matures [29][30] Question: Can you provide an estimate on cash operating expenses for 2026? - Cash operating expenses are expected to grow from approximately $35 million in 2025 to about $50 million in 2026, driven by commercial and medical expansions [31][33] Question: Can you provide an update on the Norgine partnership and ex-U.S. progress? - Norgine plans 8-10 launches in 2026, with initial revenue contributions expected in the second half of 2026 [34][35] Question: When do you expect to see initial revenue from the Norgine partnership? - Revenue contributions from Norgine are anticipated to materialize in the second half of 2026, particularly after pricing is established in Germany [60] Question: How is the company addressing the growth of treated patients in Q4? - The company is seeing significant growth in AYA patients, with a focus on both existing and new accounts, and expects this trend to continue [51][52][55]

Financial Data and Key Metrics Changes - For the full fiscal year 2025, the company recorded net product sales of $44.6 million, compared to $29.6 million in 2024, representing an increase of approximately 50% [6][21] - In the fourth quarter of 2025, net product sales were $13.8 million, compared to $7.9 million in the comparable period in 2024, representing an increase of approximately 75% [20][21] - The company achieved a record performance in patient support program Fennec HEARS, with conversion rates up 70% in Q4 compared to 50% in the first quarter [9] Business Line Data and Key Metrics Changes - The growth in net product sales is attributed to both new and existing accounts, with notable success in conversion and adherence of PEDMARK patients [21] - Selling and marketing expenses for Q4 2025 were $6.1 million, compared to $3.9 million in Q4 2024, largely due to increased payroll and marketing expenses [21][22] - General and administrative expenses for Q4 2025 were $8.9 million, compared to $4.2 million in Q4 2024, driven by higher legal expenses and increased payroll [22][23] Market Data and Key Metrics Changes - The company expanded its capabilities to include new territories and high-prescribing targets in the adolescent and young adult (AYA) market [8] - The AYA market represents a significant opportunity, with an addressable market of over 20,000 patients annually [36] Company Strategy and Development Direction - The company aims to enhance execution by increasing its customer-facing team and expanding its reach to help more cancer patients protect their hearing [7][8] - A focused strategy was outlined to expand and deepen clinical evidence supporting products via institution-led initiatives, targeting additional tumor types and patient populations [16][31] - The company plans to continue investing in growth while maintaining financial rigor, positioning itself for long-term value creation [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute plans and achieve sustained growth, emphasizing the importance of expanding awareness of cisplatin-induced ototoxicity [12][78] - The company anticipates generating positive cash flow in Q1 2026, with a strong balance sheet and zero debt outstanding [23][24] - Management highlighted the importance of ongoing dialogue with regulatory authorities regarding potential pathways for label expansion as clinical data matures [30][31] Other Important Information - The company announced the settlement of patent litigation regarding PEDMARK in the U.S., which will save millions in annual G&A and provide market exclusivity until September 1, 2033 [24][25] - The company is focused on expanding its commercial team and enhancing its operational infrastructure to ensure efficient access for patients [9][12] Q&A Session Summary Question: What is the biggest challenge or pushback from physicians regarding PEDMARK? - Management noted that the primary concern has been whether sodium thiosulfate could reduce cisplatin's anti-tumor activity, but long-term follow-up studies have shown no difference in overall survival [26][27] Question: What is Fennec's regulatory strategy for the AYA population? - The company is focused on expanding the clinical evidence base and maintaining dialogue with regulatory authorities regarding potential pathways for label expansion [30][31] Question: Can you provide an estimate on cash operating expenses for 2026? - The company anticipates cash operating expenses to grow from approximately $35 million in 2025 to approximately $50 million in 2026, focusing on commercial and medical expansions [32] Question: When would you expect to see initial revenue from the Norgine partnership? - Initial revenue contributions from Norgine are anticipated in the second half of 2026, following pricing approvals in Germany [57] Question: How is the company thinking about business development going forward? - The company sees significant opportunities in expanding PEDMARK's reach and is open to evaluating potential late-stage assets or commercial assets as it continues to grow [71]

Financial Data and Key Metrics Changes - The company reported record net product sales of $44.6 million for the full year 2025, a 50% increase from $29.6 million in 2024 [5][20] - For Q4 2025, net product sales reached $13.8 million, up approximately 75% from $7.9 million in Q4 2024 [19][20] - Selling and marketing expenses for Q4 2025 were $6.1 million, compared to $3.9 million in Q4 2024, reflecting increased payroll and marketing efforts [20][21] - General and administrative expenses for Q4 2025 were $8.9 million, up from $4.2 million in Q4 2024, driven by higher legal and payroll expenses [21][22] - Cash and cash equivalents stood at $36.8 million as of December 31, 2025, bolstered by $42 million in net proceeds from equity offerings [22][23] Business Line Data and Key Metrics Changes - The Fennec HEARS patient support program achieved record performance in Q4, with significant increases in patient enrollments and conversion rates, which rose to 70% from 50% in Q1 [8][19] - The company expanded its capabilities to target the adolescent and young adult (AYA) market, enhancing its outreach to high-prescribing targets [6][9] Market Data and Key Metrics Changes - The company is focusing on expanding awareness and use of PEDMARK, particularly among young adult testicular cancer patients, with initiatives planned around major events like the Indy 500 [9][10] - The AYA market represents a significant opportunity, with an addressable market of over 20,000 patients annually [36] Company Strategy and Development Direction - The company aims for global expansion and sustained growth, with a focus on execution and enhancing its commercial team [11][19] - Strategic initiatives include strengthening medical affairs and expanding clinical evidence generation to support product adoption [12][15] - The company plans to leverage partnerships with academic institutions to drive research and enhance product credibility [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its plans and achieve long-term value creation, citing a strong balance sheet and operational efficiency [6][11] - The company anticipates generating positive cash flow in Q1 2026, with early collection of receivables expected to benefit cash position [23] - Management highlighted the importance of ongoing dialogue with regulatory authorities regarding potential label expansions for PEDMARK [30] Other Important Information - The company announced the settlement of patent litigation regarding PEDMARK, which will provide market exclusivity until September 1, 2033, saving millions in annual G&A expenses [23][24] - The Norgine partnership is expected to contribute significantly to financials in the second half of 2026, with multiple launches planned across Europe [34][36] Q&A Session Summary Question: What is the biggest challenge or pushback from physicians regarding PEDMARK? - The primary concern has been whether sodium thiosulfate interferes with cisplatin's anti-tumor activity, but long-term studies show no difference in survival outcomes [25][26] Question: What is Fennec's regulatory strategy for the AYA population? - The company is focused on expanding clinical evidence and maintaining dialogue with regulatory authorities for potential label expansion [29][30] Question: Can you provide an estimate on cash operating expenses for 2026? - Cash operating expenses are expected to grow from approximately $35 million in 2025 to about $50 million in 2026 due to commercial expansion [31][32] Question: When will initial revenue from the Norgine partnership be expected? - Material contributions from the Norgine partnership are anticipated in the second half of 2026 following pricing approvals [58][60] Question: How is the company addressing the growth of treated patients in Q4? - The company is seeing significant growth in AYA patients and is focusing on both existing and new accounts to drive further penetration [51][52]

Core Insights - Fennec Pharmaceuticals achieved record annual revenue with net product sales of $44.6 million for the fiscal year 2025, reflecting a 50% year-over-year growth, and Q4 2025 net product sales of $13.8 million, representing a 75% increase over Q4 2024 [1][8][9] - The company executed a clinical data strategy to expand real-world validation of its product PEDMARK across new tumor types and patient populations through independent research [1][4] - Fennec reported strong patient enrollments and conversion rates in Q4 2025, indicating effective field execution and growing adoption of PEDMARK [1][3] - The company completed an oversubscribed equity offering of $42 million, enhancing its financial position [1][3] - Positive topline results were announced from a clinical study in Japan evaluating PEDMARK for reducing cisplatin-induced hearing loss [1][5] Financial Performance - For Q4 2025, net product sales were $13.8 million, up from $7.9 million in Q4 2024, marking a 75% increase [8][10] - Full-year net product sales reached approximately $44.6 million, compared to $29.6 million in 2024, a 50% increase [8][10] - Selling and marketing expenses for Q4 2025 were $6.1 million, up from $3.9 million in Q4 2024, primarily due to increased payroll and marketing efforts [8][10] - General and administrative expenses for Q4 2025 were $8.9 million, compared to $4.2 million in Q4 2024, driven by higher legal and payroll costs [8][10] - Cash and cash equivalents stood at $36.8 million as of December 31, 2025, reflecting a $10.2 million increase from the previous year [8][11] Business Highlights - Continued growth in key PEDMARK accounts, with increasing adoption among adolescent and young adult (AYA) patients across various tumor types [4][5] - Expansion of the field team to enhance customer engagement and support more cancer patients in protecting their hearing [4] - New real-world data presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium indicated the safe administration of PEDMARK in adults with head and neck cancer [4][5] - Initiation of two institution-led clinical studies evaluating PEDMARK for preventing cisplatin-induced ototoxicity in adult cancer patients [4][5] Upcoming Events - Management will host one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 15-16, 2026 [6]

Core Insights - Fennec Pharmaceuticals Inc. is set to release its fourth-quarter earnings results on March 24, with analysts expecting earnings of 4 cents per share, a significant improvement from a loss of 6 cents per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $14.73 million, which represents a substantial increase from $7.92 million a year earlier [1] Recent Developments - On March 16, Fennec Pharmaceuticals announced a settlement agreement that resolves the PEDMARK patent litigation, which positively impacted the stock price, leading to a 1.8% increase to close at $7.45 [2] - Analysts have been actively rating the company, and Benzinga provides access to the latest analyst ratings, allowing readers to sort by various criteria [2]

Core Insights - Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2025 financial results on March 24, 2026, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss the financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity, and has received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the name PEDMARQSI [3] Licensing and Market Presence - In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently available in the U.K. and Germany [4] Regulatory Status and Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents for PEDMARK that extend protection until 2039 in both the U.S. and internationally [5]

Core Insights - Fennec Pharmaceuticals has reached a settlement with Cipla regarding the litigation over Cipla's application to market a generic version of PEDMARK, with Cipla agreeing not to enter the market until September 1, 2033, or earlier under specific conditions [1] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on reducing ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [14] - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients aged 1 month and older with localized, non-metastatic solid tumors [2][6] Product Details - PEDMARK is a unique formulation of sodium thiosulfate available in single-dose, ready-to-use vials for intravenous use [2] - The product has been endorsed by the National Comprehensive Cancer Network (NCCN) for the adolescent and young adult population with a 2A recommendation [3] Market Context - Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by platinum-based chemotherapy, with many experiencing lifelong hearing loss due to ototoxicity [4] - Prior to PEDMARK's FDA approval, there were no preventative agents for hearing loss resulting from cancer treatment, significantly impacting patients' quality of life [4] Clinical Studies - PEDMARK has been validated through two Phase 3 clinical studies, COG ACCL0431 and SIOPEL 6, demonstrating its efficacy in reducing ototoxicity [5] - The COG ACCL0431 study included various childhood cancers treated with intensive cisplatin therapy, while SIOPEL 6 focused on hepatoblastoma patients [5] Regulatory and Commercialization Status - PEDMARK received FDA approval in September 2022 and has also been approved in Europe and the U.K. under the brand name PEDMARQSI [14][15] - Fennec has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand [15] - The product has Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, providing significant market protection [16]